查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1941488

免疫疗法药物市场规模、份额和趋势分析报告：按药物类型、适应症、地区和细分市场预测（2026-2033 年）

Immunotherapy Drugs Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), By Indication (Cancer, Infectious Diseases, Autoimmune Diseases), By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

免疫疗法药物市场概览

2025年全球免疫疗法市场规模估计为2,857.3亿美元，预计2033年将达到6,759.8亿美元。

预计从2026年到2033年，该市场将以11.41%的复合年增长率成长。推动该市场成长的主要因素是全球慢性病发生率的上升。

全球慢性疾病负担日益加重，包括癌症、自体免疫疾病和发炎性疾病，以及化疗和放射线治疗等传统治疗方法的限制日益凸显，推动了免疫疗法市场的发展。这些限制加速了免疫疗法的转变，免疫疗法具有标靶作用机制，能够改善患者预后。例如，世界卫生组织（世卫组织）2025年2月发布的报告显示，2020年全球癌症死亡人数约1,000万，约占全球死亡总数的六分之一。其中，乳癌病例226万例，肺癌病例221万例，大肠癌病例193万例，肺癌死亡人数达180万人。世卫组织也估计，每年约有40万例儿童癌症病例，并指出低收入和中低收入国家30%的癌症病例与感染疾病有关。这些因素进一步刺激了对先进免疫疗法的需求。

技术进步和强劲的研究活动在推动免疫疗法市场发展方面发挥关键作用。免疫肿瘤学领域，特别是细胞疗法（如免疫查核点抑制剂、单株抗体和CAR-T疗法）的显着进展，彻底改变了癌症治疗的模式。这些治疗方法已在多种固态肿瘤和骨髓恶性肿瘤中展现出高效性，从而拓展了其临床适应症。製药和生技公司正大力投资研发，以提高疗效、减少副作用并开发下一代免疫疗法。策略联盟、併购也加速了创新和产品线的扩展。此外，主要市场有利的法规结构、加速核准程序和孤儿药认定，也促进了新型免疫疗法的快速商业化，显着推动了市场成长。

除了肿瘤领域，免疫疗法市场也受惠于全球应用范围的扩大和医疗基础设施的改善，从而拓展了整体市场潜力。自体免疫、感染疾病和罕见遗传疾病的免疫疗法研究进展正在推动其更广泛的临床应用。在已开发地区，完善的医保体系、高额的医疗支出以及先进的诊断设施促进了免疫疗法的常规应用。同时，新兴经济体由于医疗体系的改善、医疗旅游的兴起以及政府旨在加强癌症治疗的倡议，也实现了稳步增长。意识提升，以及生技药品成本效益的逐步改善，进一步推动了免疫疗法的应用。这些相互关联的因素共同支撑着全球免疫疗法市场的长期成长前景和持续创新。

目录

第一章调查方法和范围

第二章执行摘要

第三章 免疫疗法药物市场变数、趋势与范围

  • 市场概况/产品线展望
  • 市场规模和成长前景
  • 市场动态
  • 免疫疗法药物市场分析工具
    • 波特分析
    • PESTEL 分析

第四章：免疫疗法药物市场：按药物类型分類的估算和趋势分析

  • 按药物类型分類的市场份额（2025 年和 2033 年）
  • 市场规模、预测与趋势分析（按药物类型划分，2021-2033 年）
  • 单株抗体
  • 免疫调节剂
  • 疫苗
  • 其他的

第五章：免疫疗法药物市场：依适应症分類的估算与趋势分析

  • 按适应症分類的市场份额（2025 年和 2033 年）
  • 市场规模、预测与趋势分析（按指标，2021-2033 年）
  • 癌症
  • 自体免疫疾病
  • 感染疾病
  • 其他的

第六章：免疫疗法药物市场：区域、预测与趋势分析

  • 2025年及2033年区域市占率分析
  • 区域市场概览
  • 市场规模及预测趋势分析，2021-2033年
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 泰国
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Amgen Inc.
    • Novartis AG
    • AbbVie Inc.
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Johnson & Johnson Services, Inc.
    • AstraZeneca
    • GSK plc.
    • Sanofi
    • Bayer AG
Product Code: GVR-4-68039-961-5

Immunotherapy Drugs Market Summary

The global immunotherapy drugs market size was estimated at USD 285.73 billion in 2025 and is expected to reach USD 675.98 billion by 2033, growing at a CAGR of 11.41% from 2026 to 2033. This market is primarily driven by the rising incidence of chronic diseases globally.

This market was driven by the rising global burden of cancer and chronic diseases, including autoimmune and inflammatory disorders, alongside the growing limitations of conventional treatments such as chemotherapy and radiation therapy. These constraints had accelerated the shift toward immunotherapy because of its targeted mechanism of action and improved patient outcomes. For instance, February 2025, the World Health Organization reported that cancer was responsible for nearly 10 million deaths in 2020, accounting for almost one in six deaths globally. Breast cancer recorded 2.26 million cases, lung cancer 2.21 million, and colorectal cancer 1.93 million, while lung cancer caused 1.80 million deaths. The organization also estimated around 400,000 childhood cancer cases annually and noted that 30 percent of cancers in low and lower middle income countries were infection related, reinforcing demand for advanced immunotherapies.

Technological advancements and robust research activity play a critical role in driving the immunotherapy drugs market forward. Significant progress in immuno-oncology, particularly in immune checkpoint inhibitors, monoclonal antibodies, and cell-based therapies such as CAR-T, has transformed cancer treatment paradigms. These therapies have demonstrated strong efficacy across multiple solid tumors and hematological malignancies, leading to expanding clinical indications. Pharmaceutical and biotechnology companies are investing heavily in research and development to improve therapeutic effectiveness, reduce adverse effects, and develop next-generation immunotherapies. Strategic collaborations, mergers, and acquisitions are also accelerating innovation and pipeline expansion. Moreover, favorable regulatory frameworks, fast-track approvals, and orphan drug designations in major markets are enabling faster commercialization of novel immunotherapy drugs, thereby contributing significantly to market growth.

Beyond oncology, the immunotherapy drugs market was supported by expanding applications and improving healthcare infrastructure worldwide, which broadened overall market potential. Immunotherapies were increasingly explored for autoimmune diseases, infectious diseases, and rare genetic disorders, enabling wider clinical adoption. In developed regions, strong reimbursement systems, higher healthcare spending, and access to advanced diagnostic facilities facilitated routine use of immunotherapy drugs. At the same time, emerging economies experienced steady growth due to improvements in healthcare systems, rising medical tourism, and government initiatives aimed at strengthening cancer care delivery. Growing awareness among patients and healthcare providers, coupled with gradual improvements in the affordability of biologic therapies, further supported uptake. Together, these interconnected factors sustained long term growth prospects and continued innovation in the global immunotherapy drugs market.

Global Immunotherapy Drugs Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global immunotherapy drugs market report based on drug type, indication, and region:

  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Monoclonal Antibodies
  • Immunomodulator
  • Vaccine
  • Others
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Thailand
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Immunotherapy Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Immunotherapy Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape.
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Immunotherapy Drugs Market: Drug Type Estimates & Trend Analysis

  • 4.1. Drug Type Market Share, 2025 & 2033
  • 4.2. Drug Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 4.4. Monoclonal Antibodies
    • 4.4.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Immunomodulator
    • 4.5.1. Immunomodulator Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Vaccine
    • 4.6.1. Vaccine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Immunotherapy Drugs Market: Indication Estimates & Trend Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 5.4. Cancer
    • 5.4.1. Cancer Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Autoimmune Diseases
    • 5.5.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Infectious Diseases
    • 5.6.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Immunotherapy Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Sweden Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Norway Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. Thailand Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. South Korea Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Australia
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Australia Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Immunotherapy Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Amgen Inc.
      • 7.5.1.1. Participant's Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Recent Developments/ Strategic Initiatives
    • 7.5.2. Novartis AG
      • 7.5.2.1. Participant's Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Recent Developments/ Strategic Initiatives
    • 7.5.3. AbbVie Inc.
      • 7.5.3.1. Participant's Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Recent Developments/ Strategic Initiatives
    • 7.5.4. Pfizer Inc.
      • 7.5.4.1. Participant's Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Recent Developments/ Strategic Initiatives
    • 7.5.5. F. Hoffmann-La Roche Ltd
      • 7.5.5.1. Participant's Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Recent Developments/ Strategic Initiatives
    • 7.5.6. Johnson & Johnson Services, Inc.
      • 7.5.6.1. Participant's Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Recent Developments/ Strategic Initiatives
    • 7.5.7. AstraZeneca
      • 7.5.7.1. Participant's Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Recent Developments/ Strategic Initiatives
    • 7.5.8. GSK plc.
      • 7.5.8.1. Participant's Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Recent Developments/ Strategic Initiatives
    • 7.5.9. Sanofi
      • 7.5.9.1. Participant's Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Recent Developments/ Strategic Initiatives
    • 7.5.10. Bayer AG
      • 7.5.10.1. Participant's Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Immunotherapy Drugs Market, by Region, 2021 - 2033 (USD Million)
  • Table 4 Global Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 5 Global Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 6 North America Immunotherapy Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 7 North America Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 8 North America Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 9 U.S. Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 10 U.S. Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 11 Canada Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 12 Canada Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 13 Mexico Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 15 Europe Immunotherapy Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 16 Europe Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 17 Europe Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 18 Germany Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 19 Germany Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 20 UK Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 21 UK Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 22 France Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 23 France Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 24 Italy Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 25 Italy Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 26 Spain Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 27 Spain Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 28 Sweden Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 29 Sweden Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 30 Denmark Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 31 Denmark Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 32 Norway Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 33 Norway Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific Immunotherapy Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 37 China Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 38 China Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 39 Japan Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 40 Japan Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 41 India Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 42 India Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 43 South Korea Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 44 South Korea Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 45 Australia Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 46 Australia Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 47 Thailand Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 48 Thailand Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 49 Latin America Immunotherapy Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 50 Latin America Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 51 Latin America Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 52 Brazil Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 53 Brazil Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 54 Argentina Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 55 Argentina Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Immunotherapy Drugs Market, by Country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 59 South Africa Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 60 South Africa Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 63 UAE Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 64 UAE Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)
  • Table 65 Kuwait Immunotherapy Drugs Market, by Drug Type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait Immunotherapy Drugs Market, by Indication, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Immunotherapy drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Immunotherapy drugs market dynamics
  • Fig. 12 Immunotherapy drugs market: Porter's five forces analysis
  • Fig. 13 Immunotherapy drugs market: PESTLE analysis
  • Fig. 14 Immunotherapy drugs market: Drug type segment dashboard
  • Fig. 15 Immunotherapy drugs market: Drug type market share analysis, 2025 & 2033
  • Fig. 16 Monoclonal antibodies market, 2021 - 2033 (USD Million)
  • Fig. 17 Immunomodulator market, 2021 - 2033 (USD Million)
  • Fig. 18 Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Immunotherapy drugs market: Indication segment dashboard
  • Fig. 21 Immunotherapy drugs market: Indication market share analysis, 2025 & 2033
  • Fig. 22 Cancer market, 2021 - 2033 (USD Million)
  • Fig. 23 Autoimmune diseases market, 2021 - 2033 (USD Million)
  • Fig. 24 Infectious diseases market, 2021 - 2033 (USD Million)
  • Fig. 25 Others market, 2021 - 2033 (USD Million)
  • Fig. 26 Immunotherapy drugs market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 35 Europe immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 46 Denmark country dynamics
  • Fig. 47 Denmark immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 59 Thailand country dynamics
  • Fig. 60 Thailand immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 65 Latin America immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina immunotherapy drugs market, 2021 - 2033 (USD Million
  • Fig. 70 MEA immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait immunotherapy drugs market, 2021 - 2033 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework